Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Oct 26;83(10):1330–1337. doi: 10.1054/bjoc.2000.1441

Structures of disease-specific serum alpha-fetoprotein isoforms

P J Johnson 1, T C W Poon 1, N M Hjelm 2, C S Ho 2, C Blake 1, S K W Ho 1
PMCID: PMC2408795  PMID: 11044358

Abstract

Alpha-fetoprotein (AFP) is widely used as a serological marker in the diagnosis of hepatocellular carcinoma (HCC) and non-seminomatous germ cell tumours (NSGCT). By application of isoelectric focusing (IEF) disease-specific AFP isoforms can be identified. Three major bands are apparent: + l (associated with ‘benign’ liver disease), + II (associated with HCC) and +III (associated with NSGCT). Recently, we have characterized the predominant glycans of human serum AFP and now report the application of these findings and electrospray ionization-mass spectrometry (ESI-MS) to the determination of the glycan composition of the isoforms present in the sera of 12 patients with HCC and of one patient with NSGCT. ESI-MS allowed simultaneous identification of various AFP glycoforms in purified serum AFP. Seven glycoforms were identified, but with different abundance in the sera of the HCC patients, whereas six glycoforms were identified in the serum from the NSGCT patient. The glycan structures of these glycoforms were deduced from their observed masses. AFP glycoforms carrying a single biantennary complex-type N-glycan appeared as the predominant glycoforms, whereas those carrying both N-glycan and O-glycan appeared as minor glycoforms. Correlation between the abundance of the AFP glycoforms and the IEF band intensity suggested that different degrees in sialylation cause the formation of isoforms. This contention was subsequently supported by the ESI-MS and kinetic in vitro desialylation studies on purified Bands + l and + lI AFPs. Our findings indicate that HCC-associated isoforms (Band + II) represent a group of glycoproteins whose carbohydrate structures are all characterized by being mono-sialylated, whereas those associated with benign liver disease and NSGCT are di- and a-sialo species, respectively. Knowledge of the structure of the tumour-specific isoforms should form an important basis for clinically useful assays. © 2000 Cancer ResearchCampaign

Keywords: hepatocellular carcinoma, non-seminomatous germ cell tumours, alpha-fetoprotein isoform, protein structure, glycosylation

Full Text

The Full Text of this article is available as a PDF (107.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aoyagi Y., Suzuki Y., Igarashi K., Saitoh A., Oguro M., Yokota T., Mori S., Suda T., Isemura M., Asakura H. Carbohydrate structures of human alpha-fetoprotein of patients with hepatocellular carcinoma: presence of fucosylated and non-fucosylated triantennary glycans. Br J Cancer. 1993 Mar;67(3):486–492. doi: 10.1038/bjc.1993.91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Buamah P. K., Harris R., James O. F., Skillen A. W. Lentil-lectin-reactive alpha-fetoprotein in the differential diagnosis of benign and malignant liver disease. Clin Chem. 1986 Nov;32(11):2083–2084. [PubMed] [Google Scholar]
  3. Burditt L. J., Johnson M. M., Johnson P. J., Williams R. Detection of hepatocellular carcinoma-specific alpha-fetoprotein by isoelectric focusing. Cancer. 1994 Jul 1;74(1):25–29. doi: 10.1002/1097-0142(19940701)74:1<25::aid-cncr2820740106>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  4. Du M. Q., Hutchinson W. L., Johnson P. J., Williams R. Differential alpha-fetoprotein lectin binding in hepatocellular carcinoma. Diagnostic utility at low serum levels. Cancer. 1991 Jan 15;67(2):476–480. doi: 10.1002/1097-0142(19910115)67:2<476::aid-cncr2820670226>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  5. Ho S., Cheng P., Yuen J., Chan A., Leung N., Yeo W., Leung T., Lau W. Y., Li A. K., Johnson P. J. Isoelectric focusing of alphafetoprotein in patients with hepatocellular carcinoma--frequency of specific banding patterns at non-diagnostic serum levels. Br J Cancer. 1996 Apr;73(8):985–988. doi: 10.1038/bjc.1996.192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Javadpour N. The role of biologic tumor markers in testicular cancer. Cancer. 1980 Apr 15;45(7 Suppl):1755–1761. [PubMed] [Google Scholar]
  7. Johnson P. J., Ho S., Cheng P., Chan A., Leung T., Yuen J. Germ cell tumors express a specific alpha-fetoprotein variant detectable by isoelectric focusing. Cancer. 1995 Apr 1;75(7):1663–1668. doi: 10.1002/1097-0142(19950401)75:7<1663::aid-cncr2820750717>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  8. Johnson P. J., Leung N., Cheng P., Welby C., Leung W. T., Lau W. Y., Yu S., Ho S. 'Hepatoma-specific' alphafetoprotein may permit preclinical diagnosis of malignant change in patients with chronic liver disease. Br J Cancer. 1997;75(2):236–240. doi: 10.1038/bjc.1997.39. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Johnson P. J., Poon T. C., Hjelm N. M., Ho C. S., Ho S. K., Welby C., Stevenson D., Patel T., Parekh R., Townsend R. R. Glycan composition of serum alpha-fetoprotein in patients with hepatocellular carcinoma and non-seminomatous germ cell tumour. Br J Cancer. 1999 Dec;81(7):1188–1195. doi: 10.1038/sj.bjc.6690828. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Johnson P. J., Portmann B., Williams R. Alpha-fetoprotein concentrations measured by radioimmunoassay in diagnosing and excluding hepatocellular carcinoma. Br Med J. 1978 Sep 2;2(6138):661–663. doi: 10.1136/bmj.2.6138.661. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Johnson P. J., Williams R. Cirrhosis and the aetiology of hepatocellular carcinoma. J Hepatol. 1987 Feb;4(1):140–147. doi: 10.1016/s0168-8278(87)80021-1. [DOI] [PubMed] [Google Scholar]
  12. Kay P. H., Wells F. C., Goldstraw P. A multidisciplinary approach to primary nonseminomatous germ cell tumors of the mediastinum. Ann Thorac Surg. 1987 Dec;44(6):578–582. doi: 10.1016/s0003-4975(10)62138-8. [DOI] [PubMed] [Google Scholar]
  13. Kew M. C., Popper H. Relationship between hepatocellular carcinoma and cirrhosis. Semin Liver Dis. 1984 May;4(2):136–146. doi: 10.1055/s-2008-1040653. [DOI] [PubMed] [Google Scholar]
  14. Lange P. H., Fraley E. E. Serum alpha-fetoprotein and human chorionic gonadotropin in the treatment of patients with testicular tumors. Urol Clin North Am. 1977 Oct;4(3):393–406. [PubMed] [Google Scholar]
  15. Lok A. S., Lai C. L. alpha-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. Hepatology. 1989 Jan;9(1):110–115. doi: 10.1002/hep.1840090119. [DOI] [PubMed] [Google Scholar]
  16. Nichols C. R., Saxman S., Williams S. D., Loehrer P. J., Miller M. E., Wright C., Einhorn L. H. Primary mediastinal nonseminomatous germ cell tumors. A modern single institution experience. Cancer. 1990 Apr 1;65(7):1641–1646. doi: 10.1002/1097-0142(19900401)65:7<1641::aid-cncr2820650731>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  17. Nomura F., Ohnishi K., Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer. 1989 Oct 15;64(8):1700–1707. doi: 10.1002/1097-0142(19891015)64:8<1700::aid-cncr2820640824>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  18. Okuda K. Early recognition of hepatocellular carcinoma. Hepatology. 1986 Jul-Aug;6(4):729–738. doi: 10.1002/hep.1840060432. [DOI] [PubMed] [Google Scholar]
  19. Ruoslahti E., Seppälä M. alpha-Fetoprotein in cancer and fetal development. Adv Cancer Res. 1979;29:275–346. doi: 10.1016/s0065-230x(08)60849-0. [DOI] [PubMed] [Google Scholar]
  20. Sheu J. C., Sung J. L., Chen D. S., Yang P. M., Lai M. Y., Lee C. S., Hsu H. C., Chuang C. N., Yang P. C., Wang T. H. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology. 1985 Aug;89(2):259–266. doi: 10.1016/0016-5085(85)90324-5. [DOI] [PubMed] [Google Scholar]
  21. Shimizu K., Katoh H., Yamashita F., Tanaka M., Tanikawa K., Taketa K., Satomura S., Matsuura S. Comparison of carbohydrate structures of serum alpha-fetoprotein by sequential glycosidase digestion and lectin affinity electrophoresis. Clin Chim Acta. 1996 Oct 15;254(1):23–40. doi: 10.1016/0009-8981(96)06369-3. [DOI] [PubMed] [Google Scholar]
  22. Smith C. J., Kelleher P. C. Alpha-fetoprotein molecular heterogeneity. Physiologic correlations with normal growth, carcinogenesis and tumor growth. Biochim Biophys Acta. 1980 Mar 12;605(1):1–32. doi: 10.1016/0304-419x(80)90020-7. [DOI] [PubMed] [Google Scholar]
  23. Stibler H. Carbohydrate-deficient transferrin in serum: a new marker of potentially harmful alcohol consumption reviewed. Clin Chem. 1991 Dec;37(12):2029–2037. [PubMed] [Google Scholar]
  24. Taketa K., Endo Y., Sekiya C., Tanikawa K., Koji T., Taga H., Satomura S., Matsuura S., Kawai T., Hirai H. A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res. 1993 Nov 15;53(22):5419–5423. [PubMed] [Google Scholar]
  25. Yamashita K., Taketa K., Nishi S., Fukushima K., Ohkura T. Sugar chains of human cord serum alpha-fetoprotein: characteristics of N-linked sugar chains of glycoproteins produced in human liver and hepatocellular carcinomas. Cancer Res. 1993 Jul 1;53(13):2970–2975. [PubMed] [Google Scholar]
  26. Yoshima H., Mizuochi T., Ishii M., Kobata A. Structure of the asparagine-linked sugar chains of alpha-fetoprotein purified from human ascites fluid. Cancer Res. 1980 Nov;40(11):4276–4281. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES